Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 325 participants.

Also called NCT01774968

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 325 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01774968
Other papers using this trial's data
  • OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015-12 DOI, PubMed 26307903 PubMed links an erratum for this paper. Erratum: PMID 27167918
  • Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial Health and quality of life outcomes, 2016-09-30 DOI, PubMed 27716283, PMC5045589 In the PMC Open Access subset under CC BY.
  • TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015-07 DOI, PubMed 25813411 PubMed links an erratum for this paper. Erratum: PMID 27472013

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01774968. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-05-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Human Regular U-500 Insulin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01774968
Content hash
b99bf9b440b7d0770135148e7cf24063bf1df45f62f816e3fd94a5eb2e7854d0